<DOC>
	<DOCNO>NCT01233960</DOCNO>
	<brief_summary>To provide open-label re-treatment PROCHYMAL subject enrol companion Protocol 603 evaluate safety subject active Crohn 's disease resistant standard Crohn 's disease therapy .</brief_summary>
	<brief_title>Evaluation PROCHYMALÂ® Treatment-refractory Moderate-to-severe Crohn 's Disease</brief_title>
	<detailed_description>Subjects receive infusion PROCHYMAL Day 42 , Day 84 , Day 126 initial infusion PROCHYMAL Protocol 603 . Each infusion contain 200 million cell . As subject require Protocol 603 entire duration participation Protocol 611 , concomitant medication safety information monitor Protocol 603 combination data two protocol</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subject must qualify , enrol , provide write ICF authorization use disclosure PHI Protocol 603 August 3 , 2010 . Subject successfully complete screen assessment Protocol 603 require Protocol 603 . Subject successfully complete full course four infusion investigational agent Days 0 , 3 , 7 , 14 Protocol 603 August 3 , 2010 . Subject must enroll Protocol 611 45th day first infusion Protocol 603 . Subject must provide write ICF authorization use disclosure PHI Protocol 611 . Subject unwilling unable adhere requirement Protocol 611 . Subject confirm respiratory distress PROCHYMAL infusion prior PROCHYMAL study . Subject serious adverse event previous PROCHYMAL study deem principal investigator study possibly probably relate PROCHYMAL also within 48 h PROCHYMAL infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Adult Stem Cell Therapy</keyword>
	<keyword>inflammation gastrointestinal tract</keyword>
</DOC>